BPC-157 vs TB-500
BPC-157 and TB-500 are the two most-asked-about recovery peptides in Australian practice. Neither is on the ARTG; both are prescribed by AHPRA-registered Australian doctors under TGA SAS-B when clinically appropriate.
BPC-157 vs TB-500 — head to head
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Class | Synthetic 15-aa pentadecapeptide (gastric-juice derived) | Synthetic fragment of thymosin beta-4 |
| Primary mechanism | Angiogenesis, VEGF/FGF modulation at the site | Actin regulation, systemic cell migration |
| Best-fit indication | Localised tendon/ligament, gut-lining support | Diffuse soft-tissue recovery, complex injuries |
| Administration | Subcutaneous (often near affected site) | Subcutaneous or intramuscular; loading + maintenance |
| AUD cost / month | $180–$320 compounded | $250–$400 compounded |
| AU legal pathway | TGA SAS-B | TGA SAS-B |
Verdict
For localised tendon or ligament injuries, BPC-157 first. For diffuse multi-site recovery, TB-500 — or the BPC + TB stack — is where Australian prescribers tend to go. The decision is per-case at consultation.
Frequently asked questions
- Can I take BPC-157 and TB-500 together in Australia?
- Yes — many Australian prescribers run the BPC + TB stack for stalled or complex recoveries when clinically justified, with both compounded by a TGA-licensed pharmacy under SAS-B.
- Which is cheaper, BPC-157 or TB-500?
- BPC-157 is generally cheaper — roughly AUD $180–$320/month compounded versus $250–$400/month for TB-500, due to the larger TB-500 molecule and synthesis cost.
Read the full profiles
Other comparisons
Be assessed by an Australian doctor
Take the free 5-minute intake. An AHPRA-registered Australian doctor will review your case and discuss the right molecule and pathway for you.
Start free assessment All peptides